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Background: Pancreatectomy affects gastrointestinal (GI) symptoms. Our purpose was to assess the
quality of life of pancreatectomy patients in relation to GI function.
Methods: Pancreatectomy patients were asked qualitative, open-ended questions about symptoms.
They also completed the Gastrointestinal Symptom Rating Scale (GSRS) for reflux syndrome, acute pain
syndrome, indigestion syndrome, diarrhoea syndrome and constipation syndrome.
Results: A total of 52 patients participated. Of these, 69% reported an improvement and 31% reported
no change in preoperative symptoms. No patients reported a worsening of symptoms. Half (50%) of the
patients experienced new, different symptoms. Median GSRS scores were 0 for reflux syndrome [inter-
quartile range (IQR): 0–1.0], 0 for acute pain syndrome (IQR: 0–1.0), 2.0 for indigestion syndrome (IQR:
1.0–4.0), 2.0 for diarrhoea syndrome (IQR: 0.5–4.5), and 0 for constipation syndrome (IQR: 0–1.0). Whipple
operation patients scored higher on the reflux syndrome (0.5 vs. 0; P = 0.08) and indigestion syndrome
(3.5 vs. 1.5; P = 0.06) domains. A total of 68% of Whipple operation patients experienced new symptoms,
compared with 32% of patients who had undergone other types of pancreatectomy (P = 0.002). Scores
of patients who had undergone surgery <2 years and >2 years earlier, respectively, did not differ.
Conclusions: Patients who underwent pancreatectomy frequently experienced an improvement in
preoperative symptoms, but also experienced new postoperative symptoms. This was more common
after Whipple operations. However, these symptoms were relatively mild in severity. These mild symptoms
seem to persist over time.
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Introduction
In the event of a diagnosis of a benign or malignant tumour of
the pancreas, a very limited number of treatment options must be
considered and pursued in order to successfully treat the patient.
In the USA in 2009, 42 470 individuals were diagnosed with pan-
creatic adenocarcinoma, for which survival rates at 5 years are
only 20% in patients with a localized tumour and are substantially
worse in those with more advanced disease.1 Surgical resection,
in operable cases, is the primary treatment modality. Although
postoperative mortality rates have improved, morbidity remains
relatively stable.2 Postoperative morbidity andmortality rates have
rightly received a great deal of attention, but it should be noted
that pancreatectomy itself can significantly alter gastrointestinal
(GI) physiology.3,4 These effects result from both decreased pan-
creatic enzyme and biliary excretions, and the impairment of the
endocrine pancreas function as evidenced by statistically signifi-
cant increases in fasting glycaemia and decreases in C-peptide
and insulin levels, potentially resulting in an increased risk for
diabetes-specific consequences.5 This major reduction in meta-
bolic capacity, as well as impacting the physiology of patients,
may also affect their quality of life (QoL) by forcing them to make
dietary alterations and limiting the extent of interpersonal social
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participation and activity. The main focus of this study was to
assess the extent to which these alterations impact on patients’
everyday lives and to determine which areas will be most affected.
The ultimate goal is to be able to better inform and counsel
patients as to what is to be expected following these types of
operation.
Materials and methods
This study was approved by the Henry Ford Hospital Institutional
Review Board.
Inclusion criteria defined participants as patients who had
undergone any type of pancreatectomy for benign or malignant
tumours and whose surgery had been conducted 1 year previ-
ously. Patients who had been operated upon for malignant disease
were required to exhibit no evidence of recurrence as acknowl-
edged by a review of their most recent medical records. Exclusion
criteria excluded patients in whom surgery had been conducted
<1 year previously, patients who continued to receive anti-
neoplastic chemotherapy or radiotherapy, patients who under-
went debridement for pancreatic necrosis caused by acute
pancreatitis, and patients who had been operated upon for pain
related to chronic pancreatitis.
Demographic data obtained included age, gender, type of pan-
createctomy and pathology. We did not gather information on
past medical history, the use of adjuvant chemotherapy or radia-
tion therapy during the treatment protocol, the occurrence of
postoperative complications, the need for additional operations,
the development of postoperative new medical conditions (e.g.
diabetes mellitus) or the use of GI medications or supplements.
Of the patients who met the inclusion criteria, relevant data
were obtained by telephone interviews with willing and coopera-
tive patients who had previously undergone pancreatectomy.
Once contact had been established and the purpose of the study
stated, in order to assess the QoL of patients in a controlled
format, questions were read in a consistent manner from a
script. This script included a sequence of corresponding response
options from which the patient was required to select an answer.
No time constraints were imposed. Responses were promptly
recorded.
Before asking the patient about current GI disorders, it was
important to establish whether or not the patient had had symp-
toms prior to his or her diagnosis and whether the patient had
developed new, immediately post-surgical symptoms. Patients
were first asked about the symptoms they had experienced prior to
surgery using an open-ended question format to which the patient
could respond by simply listing how he or she had felt or stating
that there had been no symptoms. Patients were not asked to recall
specific symptoms. Following this, the patient was asked to answer
with ‘yes’ or ‘no’ according to whether or not the operation had
changed the symptoms and then to indicate whether the opera-
tion had made these symptoms ‘better’, ‘worse’ or caused ‘no
change’. Lastly, the patient was asked if he or she had developed
any new, post-surgical symptoms using an open-ended question
format.
Prior to the introductory general open-ended question, the
patient was given the Gastrointestinal Symptom Rating Scale
(GSRS) to complete during the interview. The GSRS, created in
1988, was originally designed to assess patients with current irri-
table bowel syndrome and peptic ulcer disease based on previous
literature and experiences of pertinent patient symptoms.6 As a
result, this scale assesses five domains that have been identified as
important to GI integrity: reflux syndrome; acute pain syndrome;
indigestion syndrome; diarrhoea syndrome, and constipation
syndrome.6 Questions within each of these domains assess the
intensity, frequency, duration and impact on daily living of each
of these syndromes in order to facilitate a comprehensive under-
standing of various aspects of each syndrome. The GSRS was
chosen for this study of pancreatectomy patients because it is a
well-validated and reliable questionnaire which refers to and
assesses a broad range of GI symptoms.7 Lower and higher
scores imply the presence of less and more severe symptoms,
respectively.
Each question within the domain was put to the patient after
four response options indicating progressively increasing severity
had been read. A score of 0 for a given question indicates that the
physiologic impact of the syndrome on that individual is absent or
negligible and that negative social effects are absent. A score of 1
indicates that the physiologic impact of the syndrome is notice-
able but that negative social impact is absent.A score of 2 indicates
that the symptoms have a negative physiologic impact on the
patient and a mildly noticeable impact on his or her social per-
formance. Lastly, a score of 3 indicates that the patient experiences
great social and activity-related impairment as a result of negative
physiologic symptoms.6,7
Statistical analysis
All statistical analysis was performed using stata Version 8.0
(StataCorp LP, College Station, TX, USA). Nominal data were
analysed using the chi-squared test. As data from the GSRS were
ordinal in nature and therefore non-parametric, these data
were analysed using the Mann–Whitney U-test. A P-value of
0.05 was considered significant.
Results
Of 169 eligible pancreatectomy patients, 52 were able to be con-
tacted, were qualified to take part in the study and were willing to
participate in the telephone survey. Of the remaining 117 patients,
12 were living and unable to be contacted despite repeated
attempts to do so and the other 105 had died. Of the participating
patients, 30 had undergone a Whipple pancreatectomy, 16 had
undergone a distal pancreatectomy, three a central pancreatec-
tomy, two an enucleation, and one a total pancreatectomy. The
mean age of the patients was 62.0  13.8 years (range: 24–82
years). Thirty-three (63%) patients were female. With respect to
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time elapsed between the pancreatectomy and participating in the
survey, 14 of the patients had undergone surgery <2 years prior
to completing the GSRS and 38 had undergone surgery >2 years
prior to the survey (Table 1). Pathology findings documented
that 27 patients had been diagnosed with malignant lesions, 17
patients with cystic lesions, four patients with neuroendocrine
tumours, and four patients with non-neoplastic, benign lesions.
The distribution of pathology in relation to time elapsed to the
survey is represented in Table 2. There was no statistically signifi-
cant difference in scores for the frequency, severity and duration
of symptoms between patients who had undergone surgery >2
years and <2 years, respectively, prior to the survey. The period
between the operation and the follow-up survey ranged from
1 year to 13 years.
In response to the question on symptomatic change post-
pancreatectomy, 69% of patients reported an overall improve-
ment in preoperative symptoms and 31% reported no change. No
patients claimed a worsening of preoperative symptoms.Of the 52
patients, 50% claimed that they had developed new symptoms
they had not experienced preoperatively. Of these 50% of patients,
68% had undergone a Whipple operation and 32% had under-
gone other types of pancreatectomy (P < 0.002).
Scores on three of the five domains on the GSRS (for reflux,
constipation and acute pain syndromes) each calculated to a
median value of 0 (IQR: 0–1.0). A fourth parameter, indigestion
syndrome, generated a median score of 2.0 (IQR: 1.0–4.0). The
last parameter, diarrhoea syndrome, also had a median response
of 2.0 (IQR: 0.5–4.5) (Table 3). When results were compared for
specific operations and their outcomes, patients who had under-
gone Whipple operations were found to have higher scores in the
reflux syndrome and indigestion syndrome domains than patients
who had undergone other types of pancreatectomy, at 0.5 vs. 0
(P = 0.08) and 3.5 vs. 1.5 (P = 0.06), respectively, but these differ-
ences did not reach statistical significance.
Discussion
Both pancreatic disease, especially pancreatic cancer, and its treat-
ment affect the patient’s QoL in terms of overall general well-
being and GI function. Systemic manifestations of pancreatic
cancer include fatigue, lassitude, pain, depression and anxiety,
among others.8 These manifestations have been documented
using a variety of QoL-related instruments.9–11 In addition to sys-
temic effects, pancreatic disease manifests specific GI symptoms,
such as nausea, vomiting and diarrhoea.8 Beyond the disease itself,
pancreatic resection has been documented to affect overall well-
being and QoL.11–19 Gastrointestinal function and nutritional
status are also affected by pancreatectomy.3,20,21 Even non-
resectional procedures affect QoL and symptoms.22 This study
aimed to assess the frequency and magnitude of post-resection GI
effects on individuals and to investigate how a patient’s life might
be influenced both personally and socially as a result of the dif-
ferent types of resection for pancreatic tumours. Understanding
these changes and their natural history will allow surgeons to
counsel patients more effectively.
More than two-thirds of patients who underwent pancreatec-
tomy experienced some improvement in their preoperative symp-
toms. Importantly, however, none of the patients found that their
preoperative symptoms increased in severity. This is very impor-
tant because it indicates that pancreatectomy, while of obvious
curative intent, also improves the patient’s preoperative condi-
tion. However, as a result of the alterations to the GI tract and
metabolic capacity caused by pancreatectomy, primarily by the
Whipple operation compared with the other techniques addressed
in this study, half of the patients developed symptoms they had
not experienced prior to the operation. It is important to note
that, regardless of the post-surgical timeframe, the symptomatic
effects remained relatively constant.
With respect to the domains of reflux syndrome (heart burn
and acid regurgitation), acute pain syndrome (abdominal pain,
hunger pain and nausea) and constipation syndrome (constipa-
tion, hard stools and a feeling of incomplete evacuation), the
symptoms ranged from virtually non-existent to relatively mild.
This is certainly a very positive outcome of which to inform
patients prior to surgery. Symptoms in the indigestion syndrome
Table 1 Demographic data for study subjects (n = 52)
Pancreatectomy subtype Whipple, n = 30
Distal, n = 16
Central, n = 3
Enucleation, n = 2
Total, n = 1
Average age, years 62.0  13.8
Sex, female : male 1.73
Time since pancreatectomy <2 years, n = 14
>2 years, n = 38
Table 2 Distribution of pathology in relation to time since pancreate-
ctomy (n = 52)
Pathology <2 years, n (%) >2 years, n (%)
Malignant tumours 10 (71%) 17 (45%)
Cystic neoplasms 3 (21%) 14 (37%)
Neuroendocrine tumours 0 4 (11%)
Non-neoplastic benign lesions 1 (7%) 3 (8%)
Table 3 Scores on the Gastrointestinal Rating Scale (GSRS) (n = 52)
GSRS domain Median score Interquartile range
Reflux syndrome 0 0–1.0
Constipation syndrome 0 0–1.0
Acute pain syndrome 0 0–1.0
Diarrhoea syndrome 2.0 0.5–4.5
Indigestion syndrome 2.0 1.0–4.0
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and diarrhoea syndrome domains ranged from mild to moderate
in severity. The indigestion syndrome domain includes the symp-
toms of abdominal distension, increased flatulence, borborygmus
and eructation; patients in this study complained predominantly
of the former two symptoms. Symptoms in the diarrhoea syn-
drome domain consist of loose stools, diarrhoea and urgency
of defecation. Again, if the surgical team can acknowledge and
appreciate this and make the patient aware of what he or she
might expect, they may thereby improve the QoL of that patient
through the provision of proper counselling.
It is important to note that many of the patients verbally com-
municated that they had at times experienced their symptoms
with increased severity, and stressed that their dietary intake had
significant effects on fluctuations in their symptoms. Patients who
claimed to make consistent and appropriate postoperative use of
enzymes and particular foods, while avoiding foods known to
cause GI problems, acknowledged the importance of this practice
in preventing the exacerbation of symptoms. This underlines the
necessity of providing the patient with proper dietary counselling
in order to lessen the burden of post-surgical GI complications
and to improve social outcomes and QoL.
This study has several limitations. Firstly, it represents a cross-
sectional analysis of living patients who had no evidence of disease
recurrence.Certainly, patients with recurrent or progressivemalig-
nancy may have worse symptoms. Secondly, patients in receipt of
anti-neoplastic therapy were excluded. Therefore, immediately
postoperative patients in this groupwere not assessed in this study.
Thirdly, the data were not gathered prospectively at defined time-
points and therefore do not elucidate a natural history of symp-
tomatic change. Fourthly, although the GSRS broadly assesses a
wide variety of GI symptoms, it is possible that it did not assess
some aspects of QoL and functional status that may be important
to patients. In addition, it is difficult to know how reproducible the
GSRS is over time. For instance, a patient may give a particular
response to a given question during a primary interview and then,
in an identical secondary interview conducted after some time has
elapsed, may provide a different response to the same question
stem and response options. We did not test this variability. The
occurrence of diabetes mellitus postoperatively may also affect
QoL, but we did not gather information on this issue. Lastly, the
sample size was relatively small and therefore some differences in
functional status and QoL may have been missed.
Conclusions
In conclusion, many preoperative symptoms are improved by
pancreatic resection. Nevertheless, it is common for some new
postoperative symptoms to appear. As measured by the GSRS,
diarrhoea syndrome and indigestion syndrome appear to be the
domains of GI symptomsmost affected by pancreatectomy.None-
theless, the severity of these symptoms appears relatively mild.
Pancreatic head resections appear to result in more frequent and
possibly more severe symptoms, but, once again, the difference
is relatively small. These results may help surgeons to properly




1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009) Cancer
statistics, 2009. CA Cancer J Clin 59:225–249.
2. Simons JP, Shah SA, Sing CN, Whalen GF, Tseng JF. (2009) National
complication rates after pancreatectomy: beyond mere mortality. J Gas-
trointest Surg 13:1798–1805.
3. Ohtsuka T, Tanaka M, Miyazaki K. (2006) Gastrointestinal function and
quality of life after pylorus-preserving pancreaticoduodenectomy.
J Hepatobiliary Pancreat Surg 13:218–224.
4. Tran TC, van Lanschot JJ, Bruno MJ, van Eljick CH. (2009) Functional
changes after pancreaticoduodenectomy: diagnosis and treatment. Pan-
creatology 9:729–737.
5. Menge BA, Schrader H, Breuer TGK, Dabrowski Y, Uhl W, Schmidt WE
et al. (2008) Metabolic consequences of a 50% partial pancreatectomy in
humans. Diabetologia 52:306–317.
6. Revicki DA, Wood M, Wiklund I, Crawley J. (1998) Reliability and validity
of the Gastrointestinal Symptom Rating Scale in patients with gastroe-
sophageal reflux disease. Qual Life Res 7:75–83.
7. Svedlund J, Sjodin I, Dotevall G. (1988) GSRS – a clinical rating scale for
gastrointestinal symptoms in patients with irritable bowel syndrome and
peptic ulcer disease. Dig Dis Sci 33:129–134.
8. Labori KJ, Hjermstad MJ, Wester T, Buanes T, Loge JH. (2006) Symptom
profiles and palliative care in advanced pancreatic cancer – a prospective
study. Support Care Cancer 14:1126–1133.
9. Crippa S, Dominguez I, Rodriguez JR, Razo O, Thayer SP, Ryan DP et al.
(2008) Quality of life in pancreatic cancer: analysis by stage and treat-
ment. J Gastrointest Surg 12:783–794.
10. Velanovich V. (2011) Association of malignancy and survival with quality
of life measures in patients with pancreatic pathology. Pancreas
40:1063–1069.
11. Pezzilli R, Fantini L, Morselli-Labate AM. (2007) Pancreatectomy for pan-
creatic disease and quality of life. JOP 8 (Suppl. 1):118–131.
12. Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J et al.
(2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann
Surg 231:890–898.
13. Schmidt U, Simunec D, Piso P, Klempnauer J, Schlitt HJ. (2005) Quality
of life and functional longterm outcome after partial pancreati-
coduodenectomy: pancreaticogastrostomy versus pancreaticojejunos-
tomy. Ann Surg Oncol 12:1–6.
14. Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG
et al. (2005) Quality of life after total pancreatectomy: is it really that bad
on longterm follow-up? J Gastrointest Surg 9:1059–1067.
15. Schniewind B, Bestmann B, Henne-Bruns D, Faendrich F, Kremer B,
Kuechler T. (2006) Quality of life after pancreaticoduodenectomy for
ductal adenocarcinoma of the pancreatic head. Br J Surg 93:1099–1107.
16. Warnick SJ, Velanovich V. (2006) Correlation of patient-derived utility
values and quality of life after pancreaticoduodenectomy for pancreatic
cancer. J Am Coll Surg 202:906–911.
17. Schniewind B, Bestmann B, Kurdow R, Tepel J, Henne-Bruns D,
Faendrich F et al. (2006) Bypass surgery versus palliative pancreati-
12 HPB
HPB 2012, 14, 9–13 © 2011 International Hepato-Pancreato-Biliary Association
coduodenectomy in patients with advanced ductal adenocarcinoma of
the pancreatic head, with an emphasis on quality of life analysis. Ann
Surg Oncol 13:1403–1411.
18. Parviainen M, Raty S, Nordback I, Sintonen H, Vehkalahti P, Sand J.
(2008) Late postoperative quality of life following pancreatic head resec-
tions. Hepatogastroenterology 55:711–716.
19. Kostro J, Sledzinski Z. (2008) Quality of life after surgical treatment of
pancreatic cancer. Acta Chir Belg 108:679–684.
20. McLeod RS, Taylor BR, O'Connor BI, Greenberg GR, Jeejeebhoy KN,
Royall D et al. (1995) Quality of life, nutritional status, and gastrointestinal
hormone profile following the Whipple procedure. Am J Surg 169:179–
185.
21. McLeod RS. (1999) Quality of life, nutritional status, and gastrointestinal
hormone profile following the Whipple procedure. Ann Oncol 10:281–284.
22. Luman W, Cull A, Palmer KR. (1997) Quality of life in patients stented for
malignant biliary obstruction. Eur J Gastroenterol Hepatol 9:481–484.
HPB 13
HPB 2012, 14, 9–13 © 2011 International Hepato-Pancreato-Biliary Association
